Back to News
Market Impact: 0.2
CDT Equity Partners With QIMA Life Sciences On Autoimmune Skin Research, Shares Fall In Pre-market
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
CDT Equity entered a partnership with French contract research organization QIMA Life Sciences to evaluate several of its assets for autoimmune skin diseases. The collaboration expands development exploration for CDT's biotech pipeline, though no financial terms, clinical data, or commercialization timeline were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
CDT0.45
More News
- UBS now expects AI capex to reach nearly $1tn this year and around $1.4tn by 2027
- Warren Buffett stepping down as chairman of Berkshire Hathaway: 'Father Time always wins'
- Japan has record 100,000 people aged over 100: How societies are ageing
- Flock Offers Employees Buyouts as Customers Flee
- Anthropic’s first embedded evaluator is … Accenture?
- Volkswagen and Porsche Holding cut outlook
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Financial Research Benchmarks: What the Scores Mean
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper